Seattle Genetics throws in the towel on $2B Immunomedics deal, CEO and CSO axed in settlement
The activist investment group venBio has brought down a high profile, $2 billion collaboration deal — with $300 million in up front cash — between …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
